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E-mail: yagata@belle.shiga-med.ac.jpTo develop effective adoptive cell transfer therapy using T cell
receptor (TCR)-engineered T cells, it is critical to isolate
tumor-reactive TCRs that have potent anti-tumor activity. In
humans, tumor-infiltrating lymphocytes (TILs) have been re-
ported to contain CD8+PD-1+ T cells that express tumor-reac-
tive TCRs. Characterization of tumor reactivity of TILs from
non-human primate tumors could improve anti-tumor activity
of TCR-engineered T cells in preclinical research. In this study,
we sought to isolate TCR genes fromCD8+PD-1+ T cells among
TILs in a cynomolgusmacaquemodel of tumor transplantation
in which the tumors were infiltrated with CD8+ T cells and were
eventually rejected. We analyzed the repertoire of TCRa and b
pairs obtained from singleCD8+PD-1+T cells inTILs and circu-
lating lymphocytes and identifiedmultiple TCR pairs with high
frequency, suggesting that T cells expressing these recurrent
TCRs were clonally expanded in response to tumor cells. We
further showed that the recurrent TCRs exhibited cytotoxic ac-
tivity to tumor cells in vitro and potent anti-tumor activity in
mice transplanted with tumor cells. These results imply that
this tumor transplantation macaque model recapitulates key
features of human TILs and can serve as a platform toward pre-
clinical studies of non-human primate tumor models.
INTRODUCTION
Immune checkpoint blockade therapies have shown effectiveness in
treating human cancers with high levels of somatic mutations.1,2 In
addition, adoptive transfer of tumor-specific lymphocytes or T cell re-
ceptor (TCR)-engineered T cells hasmediated effective anti-tumor re-
sponses in several types of cancer.3,4 To develop effective adoptive cell
transfer therapy using TCR-engineered T cells, it is critical to isolate
tumor-reactive TCRs that have potent anti-tumor activity. Several
studies have shown that neoantigens derived from somatic mutations
could activate and enrich tumor-reactive T cells, which could mediate
objective clinical responses.5–7 In humans, tumor-infiltrating lympho-
cytes (TILs) have been reported to contain CD8+ T cells (cytotoxic TMolecul
This is an open access article under the CC BY-NClymphocytes, CTLs) that are reactive with mutated tumor-associated
antigens.8–11 Indeed, TILs isolated from patients can be expanded
ex vivo and used for adoptive T cell therapies, which could mediate
objective clinical responses.6,12–14 In particular, PD-1 and/or CD137
(4-1BB)-positive T cells in human TILs have shown to express tu-
mor-reactive TCRs against shared tumor antigens and neoanti-
gens.15–17 However, it has been shown that PD-1-positive T cells in
TILs are exhausted and functionally impaired.15 Furthermore, some
patients do not respond to the adoptive transfer therapy of muta-
tion-reactive TILs, probably because the adoptively transferred
T cells are highly differentiated with little proliferative potential.18
To overcome this problem, it is plausible that TCR genes could be iso-
lated from tumor-specific TILs and be introduced into CTLs in pe-
ripheral blood lymphocytes (PBLs) without impaired function to
generate tumor-reactive T cells that exhibit potent anti-tumor activity.
The development of these immune-based cancer therapies requires an
animalmodelwith an immune systemsimilar to that of humans.Mouse
tumor models have provided important insights into anti-tumor im-
mune responses; however, substantial differences between the mouse
and human immune systems hamper the clinical translation of the re-
sults obtained inmouse tumormodels.19 In addition, off-target toxicity
with tumor-reactive TCRs cannot be predicted by usingmousemodels.
Thus, tumormodels utilizing non-human primates, which are phyloge-
netically closer to humans than any other laboratory animals, are essen-
tial for the development and optimization of novel immunotherapies.20
Nonetheless, non-human primate tumor models have not been devel-
oped so far, since it is verydifficult to transformprimate cells into cancer
cells. In fact, the mechanisms underlying cellular transformation arear Therapy: Oncolytics Vol. 24 March 2022 ª 2021 The Authors. 77
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Isolation of TCR genes and TCR repertoire
analysis of CD8+PD-1+ TILs and PBLs in tumor-
transplanted cynomolgus monkey
(A) Schematic representation for isolation of TCR genes
from single CD8+PD-1+ TILs at day 14 after PTY cell
transplantation. (B) TCR repertoire of CD8+PD-1+ TILs
(Macaque #1) and PBLs (Macaque #2). The numbers of
T cells expressing the same TCR clonotype are indicated
around the pie charts. (C) V genes andCDR3 sequences of
TCRa and TCRb pairs isolated from CD8+PD-1+ TILs
(Macaque #1). (D) V genes and CDR3 sequences of TCRa
and TCRb pairs isolated from CD8+PD-1+ PB T cells of the
macaque that had been taken repeated PTY cell injection
(Macaque #2).
Molecular Therapy: Oncolyticsdifferent between rodents and primates.21 For example, inmice, inhibi-
tion of one tumor suppressor gene such as p53 and activation of one
oncogene such as Kras are sufficient to develop tumors in many cancer
models.22 In contrast, forced expression of at least four cancer-inducing
genes is required to convert normal human cells into tumorigenic
ones.21,23–25 Thus, we previously established tumor cell lines from
induced pluripotent stem cells (iPSCs) of a cynomolgus macaque car-
rying a homozygous major histocompatibility complex (MHC) haplo-
type by overexpressing six oncogenic genes.26 One tumor cell line,
termed PTY cells, exhibited a phenotype of embryonal carcinoma and
formed tumors when injected into immunodeficient NOG mice.
However, tumors were immunologically rejected within 4–5 weeks
when transplanted in MHC-matched heterozygous monkeys. The
involvement of humoral immunity as a mechanism of tumor rejection
has been shown previously, but we further characterized TILs in this
model and found that CD8+ TILs expressed high levels of IFNg and
PD-1 along with cytotoxic molecules such as perforin and granzyme
B, implying that these CD8+ TILs might be involved in tumor rejection
of this tumor transplantation model.2778 Molecular Therapy: Oncolytics Vol. 24 March 2022In this study, we sought to examinewhether TILs
and PBLs in this tumor rejection model of cyno-
molgusmacaquemay have tumor-killing activity
by isolating TCR genes from CD8+PD-1+ T cells
in TILs and PBLs and investigating their cyto-
toxic activity against PTY cells. Multiple TCRs
with high frequency showed cytotoxic activity
to PTY cells in vitro and also exhibited potent
anti-tumor activity in vivo, implying that this tu-
mor transplantation macaque model recapitu-
lates key features of human TILs and can serve
as a platform toward preclinical studies of non-
human primate tumor models.
RESULTS
Isolation of TCR genes and TCR repertoire
analysis of CD8+PD-1+ TILs and PBLs in
tumor-transplanted cynomolgus monkeys
We previously showed that CD8+ TILs in tu-
mors transplanted in cynomolgus monkeys ex-pressed IFNg and PD-1 along with cytotoxic molecules such as per-
forin and granzyme B, raising the possibility that CD8+ TILs might be
involved in tumor rejection of this tumor transplantation macaque
model,27 although it is not known that CD8+PD-1+ T cells are reactive
to tumor cells in non-human primates. To investigate this possibility,
we examined whether CD8+ TILs have tumor-killing activity by
isolating TCR genes from CD8+ TILs and analyzing their cytotoxic
activity against PTY cells. To this end, we injected PTY cells into
four separate regions of the back of an MHC-matched heterozygous
macaque (Macaque #1) and prepared TILs from the tumors resected
at day 14 before they were rejected. To isolate TCRa and b gene pairs
from single cells, we performed single-cell sorting of CD8+PD-1+
T cells in TILs, since PD-1-positive T cells in human TILs have
been shown to express tumor-reactive TCRs (Figure 1A).15,16 Then,
we succeeded to amplify TCRa and b gene pairs from 108 single
CD8+PD-1+ cells among 184 cells analyzed (58.7%) (Figure 1B).
Next, we determined the nucleotide sequences of 108 TCRa/b pairs
and analyzed their TCR repertoire (Figures 1B and 1C). All the amino
acid sequences of complementarity-determining region (CDR) 3 of
Figure 2. Expression of the TCRs isolated frommacaque CD8+PD-1+ T cells
on CTLs regenerated from human WT1-T-iPSCs
(A) Schematic of the retroviral vector for exogenous expression of TCR genes. (B)
Expression of the exogenous TCRs on regenerated CTLs was examined by the
mTCRb antibody together with GFP.
www.moleculartherapy.orgthe TCRa and b chains that were isolated from CD8+PD-1+ TILs are
shown in Table S1. We identified two TCR pairs, namely 5A9 and
5B1, both of which were found in five cells among 108 cells (4.6%),
two TCR pairs 4C2 and 4D3 found in four cells (3.7%), two TCR pairs
3E5 and 3F1 found in three cells (2.8%), five TCR pairs found in two
cells (1.9%), and the rest of the TCR pairs including 1B9, 1D4, and
1G9 were observed only in one cell among 108 cells (0.9%), indicating
that CD8+PD-1+ T cells in TILs contain T cells expressing the TCRs
with relatively high frequencies, which might be clonally expanded in
the tumor.
We also previously reported that repeated PTY cell injections into an
MHC-matched heterozygous cynomolgus macaque induced rapid tu-
mor rejection without tumor growth, suggesting that tumor-specific
lymphocytes had been expanded and were rapidly recruited from
blood to the tumor injection site.27 Thus, we also sought to isolate
TCR pairs from CD8+PD-1+ T cells in PBLs of the MHC-matched
heterozygous macaque that had taken repeated PTY cell injections
(Macaque #2). We successfully amplified 90 TCR pairs from 184 cells
analyzed (48.9%) and identified one highly frequent TCR pair, named
1385, from 37 cells among 90 cells (41.1%), suggesting that T cells ex-pressing this 1385 TCR clonotype might be clonally expanded by
repeated PTY cell injections (Figures 1B and 1D).
Expression of the TCRs isolated from macaque CD8+PD-1+
T cells on CTLs regenerated from human WT1-T-iPSCs
Next, we tested whether the TCR pairs with relatively high fre-
quencies are reactive to PTY cells by expressing these TCRs into
CTLs, because these frequently identified TCR pairs might be derived
from T cells that were clonally expanded by responding to PTY cells
in the tumor. For this experiment, CTLs derived from PBLs of cyno-
molgus macaques would be an ideal material. However, it is difficult
to obtain a great enough number of CTLs from PBLs of cynomolgus
macaques due to the inability to activate T cells properly in our exper-
imental setting. We thus took advantage of utilizing iPSCs established
from humanWT1-antigen-specific T cells (T-iPSCs), since CTLs can
be efficiently regenerated from WT1-T-iPSCs and regenerated CTLs
can be easily expanded more than 10,000-fold by repeated TCR stim-
ulation while retaining potent cytotoxic activity.28–30
To express macaque TCRs in regenerated CTLs, we constructed
retroviral vectors, in which TCRb and TCRa genes connected with
the self-cleaving p2A peptide were introduced along with GFP (Fig-
ure 2A). To improve the expression of introduced TCRs, constant re-
gions were replaced by murine counterparts modified with interchain
disulfide bond as previously described.31 We transduced regenerated
CTLs with the resultant retroviruses and examined the expression of
introduced TCRs using the antibody against mouse TCRb constant
region (mTCRb). The introduced TCRs were efficiently expressed
together with GFP in more than 90% of the transduced regenerated
CTLs (Figure 2B). We also transduced regenerated CTLs with the hu-
man TCR that recognize the cancer testis antigen NY-ESO-1 to use as
a negative control of the killing analysis described below.
The TCR pairs with relatively high frequencies have the ability to
attack PTY tumor cells in vitro
We next examined whether regenerated CTLs transduced with TCRs
show the killing activity against PTY tumor cells. To this end, we pro-
duced PTY cells expressing luciferase (PTY-Luc) and then co-
cultured PTY-Luc cells with regenerated CTLs transduced with
TCRs for 20 h, and the cytotoxic activity was assessed by measuring
the viability of the PTY-Luc cells using the luciferase assay as previ-
ously described.32,33 Apparent cytotoxicity against PTY-Luc cells
was observed for regenerated CTLs expressing the first and second
ranked TCR pairs, 5A9, 5B1, 4C2, and 4D3, found in 5 or 4 cells
among 108 cells as well as the 1385 TCR pair that was identified
from PBLs of the macaque repeatedly injected with PTY cells (Fig-
ure 3A) in a manner dependent on the concentration of effector re-
generated CTLs relative to target PTY-Luc cells (Figure 3B). In
contrast, the TCR pairs found in 3 or 1 cells and NY-ESO-1-TCR
were mostly non-cytotoxic, except that only one TCR pair 1D4 was
cytotoxic.
Next, we examined the expression of degranulation marker CD107a
on TCR-transduced regenerated CTLs upon co-culture with PTY-LucMolecular Therapy: Oncolytics Vol. 24 March 2022 79
Figure 3. Functional analysis of TCR-transduced
regenerated CTLs
(A) Cytotoxicity of TCR-transduced regenerated CTLs
against PTY cells upon co-culture with PTY-Luc cells for
20h at E:T ratio of 1:1. The human TCR that recognizes
the NY-ESO-1 antigen was used as a negative control. (B)
Cytotoxicity of TCR-transduced regenerated CTLs
against PTY cells at different E:T ratios. Representative
data (mean ± SD) from two independent experiments are
shown in (A) and (B). (C) Expression of CD107a and IFNg
of TCR-transduced regenerated CTLs upon co-culture
with PTY-Luc cells (+) or without PTY-Luc cells () for 6 h
at E:T ratio of 1:1. (D) Cytotoxicity of TCR-transduced
regenerated CTLs against iPSCs upon co-culture with
iPSCs-Luc cells for 20 h at E:T ratio of 3:1.
Molecular Therapy: Oncolyticscells for 6 h, since CD107a expression on CTLs is associated with the
perforin-granzyme-mediated activation of apoptosis of target cells.34
Regenerated CTLs expressing the TCRs with killing activity such as
5A9, 5B1, 4C2, 4D3, 1D4, and 1385, but not those expressing the
TCRs without killing activity and NY-ESO1-TCR, expressed
CD107a when co-cultured with PTY-Luc cells, but did not express
CD107a when cultured alone (Figure 3C). We also examined IFNg
expression by intracellular staining and found that regenerated
CTLs expressing 5A9, 5B1, and 1385 TCRs markedly expressed
IFNg when co-cultured with PTY-Luc cells, but did not express
IFNg when cultured alone (Figure 3C). In addition, regenerated
CTLs expressing 4C2, 4D3, and 1D4 TCRs marginally expressed
IFNg, whereas regenerated CTLs expressing other TCRs without
cytotoxic activity did not. It might be plausible that IFNg expression
was less efficiently detected than CD107a expression because higher
TCR affinity is required to express IFNg compared to CD107a
expression.35 These results indicate that the TCRs with cytotoxic ac-
tivity have the ability to mediate the expression of CD107a and IFNg
in response to PTY cells.80 Molecular Therapy: Oncolytics Vol. 24 March 2022Multiple TCR pairs with cytotoxic activity
specifically react with PTY cells, but not
with the parental iPSCs
Even though transplantation was carried out be-
tween MHC-matched macaques, macaques are
out bred, so many gene loci other than the
MHC locus, which include minor histocompati-
bility antigen loci, are polymorphic. Thus, one
might argue that the TCRswith cytotoxic activity
may recognize minor histocompatibility anti-
gens, rather than tumor-specific antigens or neo-
antigens. To address this issue, we examined the
reactivity of the TCRs with cytotoxic activity to
the parental iPSCs, which we used to establish
PTY cells by overexpressing six oncogenic genes.
AmongTCRs that are capableof killingPTYcells,
5A9, 5B1, and 1385 TCRs do not react with the
parental iPSCs, but specifically react with PTY
cells (Figures 3A and 3D), indicating that theseTCRs donot react withminor histocompatibility antigens, but are likely
to react with tumor-specific antigens. However, the remaining TCRs
that have killing ability, 4C2, 4D3, and 1D4, react with both PTY and
iPSCs (Figures 3A and 3D), so we cannot completely exclude the possi-
bility that these TCRs react withminor histocompatibility antigens.We
have also examined whether the PTY-specific TCRs, 5A9, 5B1, and
1385, react to the products of six oncogenic genes that we introduced
into the parental iPSCs.Wehave confirmed that T cells expressing these
TCRs do not kill iPSCs that overexpress the respective oncogenic genes
one by one (data not shown), suggesting that these TCRs are likely to
react with tumor-specific antigens other than the six oncogenic gene
products. However, we cannot strictly conclude that these TCRs are tu-
mor-specific unless we identify the peptides that these TCRs recognize
and confirm that the peptides are tumor-specific antigens.
TCRs able to kill PTY cells in vitro show potent anti-tumor
activity in vivo
We further assessed whether regenerated CTLs expressing the TCRs
with cytotoxic activity in vitro show anti-tumor activity in vivo. To
Figure 4. The anti-tumor activity of TCR-transduced
regenerated CTLs in vivo
(A) Experimental protocol. (B) Tumor volume in individual
mice (n = 6 per group, except for 3E5, n = 5). (C) Tumor
volume on day 16 (**p < 0.01, analyzed by two-way
repeated measures ANOVA; NS, not significant). (D)
Percent of survival in each group (**p < 0.01, analyzed by
log rank test; NS, not significant). The results shown in (B)–
(D) are combined data of two independent experiments.
(E) Immunostaining of human CD8-positive cells (red) in
tumors. Pictures in lower panels (400) are magnification
of areas indicated by rectangles in upper panels (100).
Scale bars indicate 100 mm in upper panel and 20 mm in
lower panel.
www.moleculartherapy.orgthis end, we transplanted immunocompromized NSG mice with
PTY-Luc cells subcutaneously, and after five days of transplantation,
regenerated CTLs that were not transduced (No TCR) and regener-
ated CTLs expressing the 3E5 TCR that did not show killing activity,
the 5A9 and 1385 TCR that showed killing activity in vitrowere trans-
ferred intravenously, and IL-2, IL-7, and IL-21 were administered
intraperitoneally as shown in Figure 4A. When regenerated CTLs ex-
pressing the 3E5 TCR were transferred, tumor growth was not in-
hibited (Figures 4B and 4C), and the survival of mice was not pro-
longed when compared with regenerated CTLs that did not express
exogenous TCR (Figure 4D). In contrast, when regenerated CTLs ex-
pressing the 5A9 and 1385 TCR were transferred, tumor growth was
significantly inhibited (Figures 4B and 4C), and the survival of mice
was also significantly prolonged (Figure 4D), indicating that regener-
ated CTLs expressing the TCRs able to kill PTY cells in vitro also show
potent anti-tumor activity in vivo.
Some mice in another similarly designed experiment were sacrificed
on day 8 (after twice CTL injection on day 5 and 7), and tumor lesions
were examined by immunohistochemistry. Infiltration of human
CD8-positive T cells with blastic appearance was observed in the tu-Moleculamors when regenerated CTLs expressing the
5A9 and 1385 TCR were transferred, but not
when regenerated CTLs expressing non-exoge-
nous TCR or the 3E5 TCR were transferred
(Figure 4E). These results indicate that upon in-
jection into tumor-bearing mice, regenerated
CTLs expressing the TCRs with cytotoxic activ-
ity can infiltrate the tumor and show anti-tumor
activity by responding to PTY cells in vivo.
DISCUSSION
In this study, we first isolated TCR genes from
CD8+PD-1+ T cells infiltrating the tumor that
is eventually rejected in MHC-matched ma-
caques because PD-1-positive T cells in human
TILs have been shown to express tumor-reactive
TCRs. We succeeded to obtain multiple tumor-
reactive TCRs from the PD-1-positive popula-tion of CD8+ TILs and PBLs in this tumor transplantation macaque
model. This finding indicates that PD-1 is useful as a marker for tu-
mor-reactive T cells even in non-human primates. However, several
studies have reported that tumor-reactive TCRs can also be success-
fully isolated from CD137-positive human and mouse TILs.17,36,37 In
line with this notion, it has been reported that clonally expanded
T cells expressing the same clonotypic TCR are present in PD-
1+CD137+CD8+ TILs in patients of multiple cancer types.36 Because
PD-1 and CD137 are expressed on activated mouse and human
T cells,38,39 their finding implies that those clonally expanded popu-
lations responded to certain tumor components such as tumor
antigens.36 Although we have not utilized CD137 as a prospective
identification marker, it would be feasible to use CD137 instead of
PD-1 or in combination with PD-1 for isolation of tumor-reactive
TCRs in our macaque model.
Likewise, tumor-reactive TCRs can also be successfully isolated from
CD8+PD-1+ TILs in human melanoma.16,40 However, a recent study
reported that tumor reactivity of TCRs isolated from TILs in human
ovarian and colorectal cancers was low and variable between individ-
uals, and some patients did not show reactivity, even though theyr Therapy: Oncolytics Vol. 24 March 2022 81
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Thus, we consider that the possible reasons for the effective tumor
reactivity of TCRs in our macaque model are as follows. First, natu-
rally occurring human cancers are formed by overcoming their im-
mune system,42 whereas in our tumor transplantation macaque
model, tumor cells that have not been exposed to the immune system
are transplanted into the macaques, in which their immune system
can effectively respond to tumor cells, thereby enabling the rejection
of tumor. Second, the immune system of macaques might have higher
reactivity to tumors than that of humans, based on the observation
that spontaneous neoplasms and malignant tumors in cynomolgus
monkeys are extremely rare.43 We further showed that the multiple
TCRs with relatively high frequency isolated from macaque TILs ex-
hibited apparent cytotoxicity against PTY cells both in vitro and
in vivo, suggesting that tumor-infiltrating CD8+ T cells are likely to
contribute to the rejection of tumor in this tumor transplantation ma-
caque model. In addition, we previously reported that humoral im-
munity, including autoantibodies against a heat shock protein
GRP94, plays a role in cancer immune surveillance.26 Thus, these
multiple mechanisms including humoral immunity and T-cell-medi-
ated cytotoxicity might be another reason for the efficient rejection of
tumors in this macaque model.
Furthermore, we previously showed that repeated PTY cell injection
into the same cynomolgus macaque induced rapid tumor rejection
without tumor growth, suggesting that tumor-specific lymphocytes
had been expanded and were rapidly recruited from blood to the tu-
mor injection site.27 Indeed, we could identify the highly frequent
TCR pair 1385 from CD8+PD-1+ PBLs that showed potent cytotoxic
activity, suggesting that T cells expressing the 1385 TCR clonotype
were clonally expanded by repeated PTY cell injection and were
rapidly recruited from blood to the tumor injection site, thereby
enabling the rapid elimination of PTY cells. Although the 1385
TCR was isolated from PD-1+ PBLs of an artificial repeated injection
macaque model, recent studies reported that neoantigen-reactive
TCRs were successfully isolated from PD-1+ PBLs of patients with
naturally occurring melanoma and gastroesophageal cancer,40,44 sug-
gesting that PD-1+ PBLs would serve as an attractive cell source for
isolation of tumor-reactive TCRs. In line with our data, tumor-reac-
tive TCRs were identified based on their frequency in the CD8+ TIL
compartment of fresh human tumor samples, enabling the isolation
of tumor-reactive TCRs without prior knowledge of their antigen
specificity.36,37,45 However, in the case of cancers with low mutational
burden, in which tumor-reactive T cells are rare, it would be difficult
to identify tumor-reactive TCRs simply based on their frequency. For
these types of cancers, it would be necessary to identify TCRs that can
respond to target mutated peptides and/or to autologous tumor cells.
Because of the differences in the immune systems of mice and hu-
mans, it is necessary to study cancer immunity using non-human pri-
mates, which have immune systems more similar to those of humans.
Along with the present study, we have shown that the macaque model
may be useful for analyzing TILs that generally play major roles in the
immunological rejection of tumors and optimizing the efficacy of new82 Molecular Therapy: Oncolytics Vol. 24 March 2022immunotherapies.27 Furthermore, the mechanisms underlying
cellular transformation are different between rodents and primates.21
Whereas in mice, inactivation of one tumor suppressor gene and acti-
vation of one oncogene are sufficient to cause cancer, forced expres-
sion of at least four cancer-inducing genes is required to convert
normal human cells into tumorigenic ones.21,23–25 Therefore, the gen-
eration of monkeys in which the p53 gene is mutated by genome
editing has already been reported.46 However, it is unlikely that p53
deficiency alone will cause the development of tumors. Although
non-human primate models capable of developing tumors in the
presence of a normal immune system have not yet been reported,
we have recently succeeded in generating a model of cynomolgus ma-
caques in which four cancer-inducing genes can be inducibly ex-
pressed by doxycycline. If tumors can be developed by overcoming
the immune system in this macaque model, it will be very useful
for optimizing the efficacy of new immunotherapies and for future
human applications.
In this study, we took advantage of utilizing CTLs regenerated from
WT1-T-iPSCs since regenerated CTLs can be easily expanded by
TCR stimulation while retaining potent cytotoxic activity.28–30 How-
ever, producing regenerated CTLs fromWT1-T-iPSCs is a very time-
consuming process because WT1-T-iPSCs were first established from
WT1 antigen-specific CTLs by reprogramming, and then CTLs were
regenerated from WT1-T-iPSCs. Thus, we have developed a rapid
method, in which tumor antigen-specific TCR genes were directly
introduced into iPSCs to produce TCR-iPSCs, and then CTLs were
regenerated from TCR-iPSCs.28–30 Furthermore, in this study, we
were able to show for the first time to our knowledge that it is possible
to directly introduce exogenous TCR genes into regenerated CTLs
and obtain large numbers of tumor-killing CTLs quite rapidly. It is
also feasible that if we use CTLs regenerated from iPSCs homozygous
for frequent HLA-haplotypes, those CTLs can be transferred into
HLA haplotype-heterozygous recipients with minimal immune reac-
tion. Combined with our single-cell TCR cloning method, these ap-
proaches would be very useful, and there is a lot of potential for future
applications for human cancer. In summary, this study provides the
first evidence that cynomolgus macaque would be an ideal model
for cancer immunotherapy in terms of being not only evolutionally




Plat-E47 PG1348 and PTY cells26 weremaintained in Dulbecco’sMEM
medium (DMEM) (FUJIFILMWako, 044-29765) supplemented with
10% fetal bovine serum (FBS) (Thermo Fisher Scientific) and 1X Peni-
cillin Streptomycin Glutamine (PSG) (Thermo Fisher Scientific,
10378-016). Plat-E was kindly provided from Professor Toshio
Kitamura (University of Tokyo) and PG13 was purchased from the
American TypeCulture Collection. Regenerated CTLs, whichwere re-
generated from #3-3-WT1-T-iPSCs (HLA-A*24:02-restricted), were
maintained in aMEM medium (Thermo Fisher Scientific, 11900-
073) supplemented with 20% FBS, human Interleukin-7 (hIL-7)
www.moleculartherapy.org(5 ng/mL; PeproTech, AF-200-07), hIL-21 (10 ng/mL; PeproTech,
AF-200-21), and ascorbic acid (100 mM; nacalai tesque, 13571-
56).28,29 An autologous lymphoblastoid cell line (LCL) was established
from peripheral blood of a healthy donor from whom #3-3-WT1-T-
iPSCs were established as described29 and maintained in RPMI 1640
medium (FUJIFILM Wako, 189-02025) supplemented with 10%
FBS and 1XPSG. A luciferase expressing cell line, PTY-Luc, was estab-
lished by lentiviral transduction of pHIV-Luc-ZsGreen (Plasmid
#39196, Addgene) as described.28
Animal care
All protocols for animal experiments were approved by the Shiga
University of Medical Science Animal Experiment Committee
(Permit numbers: 2019-9-7, 2019-9-7H1, and 2019-9-7H2). The an-
imal experiments were carried out in strict accordance with the
Guidelines for the Husbandry and Management of Laboratory Ani-
mals of the Research Center for Animal Life Science at Shiga Univer-
sity of Medical Science, the guidelines of an Institutional Animal Care
and Use Committee and Standards Relating to the Care and Funda-
mental Guidelines for Proper Conduct of Animal Experiment and
Related Activities in Academic Research Institutions under the juris-
diction of the Ministry of Education, Culture, Sports, Science and
Technology, Japan. Regular veterinary care and monitoring, balanced
nutrition, and environmental enrichment were provided by the
Research Center for Animal Life Science at the Shiga University of
Medical Science.
Tumor transplantation in cynomolgus macaques
Cynomolgus macaques (Macaca fascicularis), both MHC homozy-
gous and heterozygous for a particular set of Mafa haplotype alleles
called HT1, were identified in the Filipino macaque population.
Establishment of iPSCs from an MHC homozygous cynomolgus ma-
caque and generation of iPSC-derived tumors cells (PTY cells) were
performed as described.26,27 Under ketamine/xylazine anesthesia,
2  107 PTY cells were injected into the subcutaneous tissue of
four separate regions of the back of an MHC-matched heterozygous
macaque (Macaque #1), and TILs were prepared from the tumors re-
sected at day 14 before they were rejected. In one experiment, PTY
cells were repeatedly transplanted into another individual macaque
(Macaque #2), from which PBLs were prepared.
TIL preparation and single-cell RT-PCR
Leukocytes were isolated from peripheral blood after the lysis of red
blood cells with ammonium-chloride-potassium (ACK) buffer. For
TIL isolation, resected tumors were minced and then incubated
in RPMI 1640 containing 2 mg/mL collagenase D (Roche,
11088858001) and 100 mg/mL DNase I (Roche, 4536282001) at
37C for 1 h. Single-cell RT-PCR was performed essentially
as described.49 CD8+PD-1+ T cells were single-cell-sorted by
FACSAria III (Becton Dickinson) into individual wells of 96-well
PCR plates (Bio-bik, 3401-00) that contained 10 mL of Lysis/Binding
Buffer (Thermo Fisher Scientific, DB61021) composed of 33 mg of
Dynabeads Oligo(dT)25 (Thermo Fisher Scientific, DB61021) and 1
pmol of each RTa, RTb1, and RTb2 primer. After 5 min incubation,the Lysis/Binding Buffer was removed using Dynal MPC-9600
(Thermo Fisher Scientific, 120.06D). Ten microliters of the reverse
transcription solution containing 100 U SuperScript III (Thermo
Fisher Scientific, 18080-051), 5 mM MgCl2, 0.5 mM each dNTP,
10 mM DTT, 20 U RNaseOUT (Thermo Fisher Scientific, 18080-
051), 0.2% Triton X-100, and 1X First-Strand Buffer (Thermo Fisher
Scientific, 18080-051) were added in each well, and incubated at 50C
for 50 min. The solution was replaced with 10 mL of the G-tailing so-
lution containing 0.8 U terminal deoxynucleotidyl transferase (TdT)
(New England Biolabs, M0315), 0.5 mM dGTP, 0.25 mM CoCl2, 5 U
Qiagen RNase inhibitor (Qiagen, 129916), 5 U Porcine liver Ribonu-
clease Inhibitor (Takara, 2311A), 0.2% Triton X-100, and 1X TdT
buffer (New England Biolabs, M0315) and incubated at 37C for
40 min. The solution was replaced with 19 mL of the first PCR solu-
tion. The first PCR was performed using KOD-FX polymerase
(Toyobo, KFX-101) with F1st, R1sta, R1stb1, and R1stb2 primers.
The resultant PCR mixtures were diluted 4-fold with water, and
0.5 mL of the diluted PCR mixtures was added to 12 mL of the second
PCR solution. The second PCR was performed using KOD-FX poly-
merase with F2nd primer and a primer specific for the constant region
of TCRa (R2nda), TCRb1 (R2ndb1), or TCRb2 (R2ndb2). The sec-
ond PCR products were analyzed with the R2nda, R2ndb1, or
R2ndb2 primer by direct sequencing. The TCR repertoire was
analyzed with reference to human TCR gene sequence using the
IgBLAST (https://www.ncbi.nlm.nih.gov/igblast/). Several clones
were selected based on their frequencies and subcloned into the
pENTR1A vector (Thermo Fisher Scientific). The resulting vectors,
pENTR1A-macaque TCRa and pENTR1A-macaque TCRb, were
used for retroviral vector construction. All the oligonucleotide se-
quences and PCR protocols are described in Table S2.
Construction of the TCR expression vectors
Variable region genes of the selected macaque TCRa (maVa) and
TCRb (maVb) pairs were amplified by PCR from pENTR1A-ma-
caque TCRa and pENTR1A-macaque TCRb, respectively. The
codon-optimized mouse TCRa constant region (muCa) and
the codon-optimized mouse TCRb constant-2 region linked to
the self-cleaving p2A peptide (muCb2-p2A) were synthesized
(Genscript) and subcloned into the pENTR1A vector
(pENTR1A-muCa and pENTR1A-muCb2-p2A). Both of the
mouse-constant regions were modified to contain an additional
cysteine residue to increase exogenous TCR pairing and decrease
mispairing with the endogenous TCR.31 The muCb2-p2A frag-
ment was excised from the pENTR1A-muCb2-p2A by AflII and
EcoRI digestion. The pENTR1A-muCa vector was linearized
by HindIII digestion. Then the three fragments of maVb,
muCb2-p2A, and maVa were assembled into the linearized
pENTR1A-muCa by Gibson Assembly Master Mix (New England
Biolabs, E2621S). The 1G4 TCR gene specific for the human can-
cer testis antigen NY-ESO-150 was constructed as described
above. The TCRb-p2A-TCRa gene blocks were transferred to
pMXs-RfA-IRES-EGFP by Gateway LR reaction (Thermo Fisher
Scientific, 11791-020). The resulting vector, pMXs-TCRb-p2A-
TCRa-IRES-EGFP, was used for retrovirus production.Molecular Therapy: Oncolytics Vol. 24 March 2022 83
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regenerated CTLs
The constructed plasmid vector, pMXs-TCRb-p2A-TCRa-IRES-GFP
was then transfected into Plat-E cells using polyethylenimine (Poly-
sciences, Inc., 24765-1). The culture supernatants collected 72 h after
transfection were used to infect PG13 cells in the presence of poly-
brene (4 mg/mL; Sigma, H9268). The supernatants of PG13 cells
collected 14–21 days after infection were used to transduce CTLs re-
generated from human iPSCs. Regenerated CTLs (2  105 cells/well
in 24-well plates) were co-cultured with 50 Gy irradiated HLA-
A*24:02+ LCL cells loaded with 100 nM WT1 synthetic peptide
(CYTWNQMNL, Eurofins Genomics). After 3 days of co-culture, re-
generated CTLs were collected and resuspended in retroviral super-
natants from the infected PG13 cells, seeded at the density of 5 
104 cells/well in 24-well plates coated with RetroNectin (Takara Bio
Inc., T100) and centrifuged at 1,220  g at 32C for 2 h, followed
by incubation at 37C in 5% CO2. The viral supernatant was replaced
with aMEM medium 1 h after incubation. Regenerated CTLs were
cultured at 37C in 5%CO2 and subjected for flow cytometric analysis
to evaluate the efficiency of TCR transduction 3 days after infection or
for in vitro cytotoxicity assay and in vivo anti-tumor activity assay
10–14 days after infection.
Flow cytometry
The monoclonal antibodies (mAbs) used for flow cytometric analyses
were purchased from BD Biosciences, eBioscience, or BioLegend, and
included those to CD3 (SP34-2), CD4 (OKT4), CD8a (SK1 and
HIT8a), CD45 (D058-1283), PD-1 (EH12.2H7), CD107a (H4A3),
IFNg (4S.B3), and mTCRb (H57-579). Seven-aminoactinomycin D
(7-AAD) was used to distinguish between live and dead cells. For
analysis and single-cell sorting of PBLs, cells were incubated with
human Fc receptor blocking reagent (Miltenyi Biotec) for 10 min, fol-
lowed by staining with mAbs for 60 min on ice and washing. For anal-
ysis of regenerated CTLs, cells were incubated with mAbs for 30 min
on ice and washed. Data were acquired on a FACSAria III or a
FACSCalibur (BD Biosciences) and were analyzed using FlowJo soft-
ware (Tree Star).
In vitro cytotoxicity assay using the luciferase assay
The cytotoxicity of regenerated CTLs transduced with TCR genes was
determined by luciferase assay as described.28 Briefly, TCR-trans-
duced regenerated CTLs and PTY-Luc cells (1  104) were seeded
in 96-well plates (Corning, 3917) at the indicated effector to target
(E:T) ratio and cultured for 20 h. The luciferase activity was measured
using Bright-Glo Luciferase Assay System (Promega, E2610) and
expressed as relative light units (RLU). Target cells alone were
cultured to measure the maximal luciferase activity (RLUmax). The
percentage of lysis was calculated as follows: % lysis = (1  (RLU)/
(RLUmax))  100.
Analyses of the expression of CD107a and IFNg
TCR-transduced regenerated CTLs (1  105) and PTY-Luc cells
(1  105) were seeded in round-bottom 96-well plates (Falcon,
353077) and cultured in the presence of anti-CD107a antibody for84 Molecular Therapy: Oncolytics Vol. 24 March 2022CD107a staining or 2 mM monensin for IFNg intracellular staining,
respectively. Six hours later, cells were collected and stained with
anti-CD8 antibody to distinguish regenerated CTLs from PTY-Luc
cells, and CD107a expression was analyzed by flow cytometry. For
intracellular IFNg staining, cells were stained with anti-CD8 anti-
body, fixed with 4% paraformaldehyde/PBS for 5 min at room tem-
perature, and permeabilized with the saponin solution containing
0.1% saponin, 0.1% BSA, and 10 mM HEPES (pH 7.5), followed by
staining with anti-IFNg antibody and subsequent flow cytometric
analysis.
In vivo anti-tumor activity assay using NSG mice
Female NSG mice were purchased from the Jackson Laboratory and
Charles River Japan Inc. All mice were 8 weeks old at the beginning
of each experiment. On day 0, 5  106 PTY-Luc cells suspended in
100 mL of PBS were mixed with an equal volume of Matrigel (Corn-
ing, 356237) and injected subcutaneously into the lateral abdomen
of mice. On day 5, tumor engraftment was confirmed by measure-
ment of tumor size, and each mouse was uniformly allocated to
the control or TCR group based on the size of tumors. The
mice in the control and TCR group were intravenously injected
with untransduced regenerated CTLs and TCR-transduced regener-
ated CTLs, respectively, three times per week for three weeks (5 
106 cells/injection). Cytokines (hIL-2 [PeproTech, AF-200-02]
40 ng, hIL-7 40 ng, hIL-21 40 ng/body) were injected intraperitone-
ally just after regenerated CTLs injection. Tumor-bearing mice were
sacrificed when the tumor reached 20 mm in size for ethical consid-
erations. Tumor volume was calculated by the formula ab2/2
(a, width; b, length) as described.26
Immunohistochemistry of TILs
PTY-Luc cells were injected into NSG mice as described above. Re-
generated CTLs and cytokines were injected into NSG mice on day
5 and day 7 after PTY-Luc cell injection. Tumors were removed on
day 8 and fixed overnight at 4C in formalin, followed by paraffin
embedding. Immunohistochemistry was performed essentially as
described.26 Briefly, formalin-fixed and paraffin-embedded graft tis-
sues were sectioned, followed by deparaffinization and rehydration.
Sections were incubated with anti-CD8 antibody (clone: SP16, abcam
101500) overnight at 4C, followed by incubation with the secondary
antibody conjugated with alkaline phosphatase (NICHIREI Biosci-
ence 424261) for 1 h at room temperature, and the immunoreaction
was visualized by Fast Red II (NICHIREI Bioscience 415261). Then,
sections were counter-stained with hematoxylin according to a stan-
dard protocol.
Data analysis
All the data with error bars are presented as mean ± SE. Difference
was assessed using one-way ANOVA or log rank test using Prism
software (GraphPad). Values of p < 0.05 were considered significant.
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Supplemental Table S1. V(D)J genes and CDR3 amino acid sequences of the TCR genes isolated from CD8+PD-1+ T cells in TILs of Macaque                   
ID TRBV  TRBD  TRBJ  CDR3 aa seq.  TRAV  TRAJ  CDR3 aa seq.  TCR pair 
1. TRBV7-2*01 TRBD2*01 TRBJ1-2*01 ASRPGGYDYT  TRAV23  TRAJ54*01 AAVSAQGAQKLV  5A9 
2. TRBV7-2*01 TRBD2*01 TRBJ1-2*01 ASRPGGYDYT  TRAV23  TRAJ54*01 AAVSAQGAQKLV 
3. TRBV7-2*01 TRBD2*01 TRBJ1-2*01 ASRPGGYDYT  TRAV23  TRAJ54*01 AAVSAQGAQKLV 
4. TRBV7-2*01 TRBD2*01 TRBJ1-2*01 ASRPGGYDYT  TRAV23  TRAJ54*01 AAVSAQGAQKLV 
5. TRBV7-2*01 TRBD2*01 TRBJ1-2*01 ASRPGGYDYT  TRAV23  TRAJ54*01 AAVSAQGAQKLV 
 
6. TRBV21-1*01 TRBD1*01 TRBJ1-2*01 ASSKGPQGTYDYT TRAV13-1*01 TRAJ10*01 AASIEGGGNKLT  5B1 
7. TRBV21-1*01 TRBD1*01 TRBJ1-2*01 ASSKGPQGTYDYT TRAV13-1*01 TRAJ10*01 AASIEGGGNKLT 
8. TRBV21-1*01 TRBD1*01 TRBJ1-2*01 ASSKGPQGTYDYT TRAV13-1*01 TRAJ10*01 AASIEGGGNKLT 
9. TRBV21-1*01 TRBD1*01 TRBJ1-2*01 ASSKGPQGTYDYT TRAV13-1*01 TRAJ10*01 AASIEGGGNKLT 
10. TRBV21-1*01 TRBD1*01 TRBJ1-2*01 ASSKGPQGTYDYT TRAV13-1*01 TRAJ10*01 AASIEGGGNKLT 
 
11. TRBV2*01 –  TRBJ1-1*01 ASSELRNTEAF  TRAV36  TRAJ29*01 AVLNSGNRALV  4C2 
12.  TRBV2*01 –  TRBJ1-1*01 ASSELRNTEAF  TRAV36  TRAJ29*01 AVLNSGNRALV 
13. TRBV2*01 –  TRBJ1-1*01 ASSELRNTEAF  TRAV36  TRAJ29*01 AVLNSGNRALV 
14. TRBV2*01 –  TRBJ1-1*01 ASSELRNTEAF  TRAV36  TRAJ29*01 AVLNSGNRALV 
 
15. TRBV5-6*01 TRBD2*02 TRBJ2-3*01 ASSLVRGLSDPQY TRAV27*01 TRAJ52*01 AGAGGAGYGKL  4D3 
16. TRBV5-6*01 TRBD2*02 TRBJ2-3*01 ASSLVRGLSDPQY TRAV27*01 TRAJ52*01 AGAGGAGYGKL 
17. TRBV5-6*01 TRBD2*02 TRBJ2-3*01 ASSLVRGLSDPQY TRAV27*01 TRAJ52*01 AGAGGAGYGKL 
18. TRBV5-6*01 TRBD2*02 TRBJ2-3*01 ASSLVRGLSDPQY TRAV27*01 TRAJ52*01 AGAGGAGYGKL 
 
19. TRBV2*01 TRBD2*01 TRBJ2-5*01 ASSEAGTPLGETQY TRAV8-4*01 TRAJ31*01 AVNDRDNNARVI  3E5 
20. TRBV2*01 TRBD2*01 TRBJ2-5*01 ASSEAGTPLGETQY TRAV8-4*01 TRAJ31*01 AVNDRDNNARVI 
21. TRBV2*01 TRBD2*01 TRBJ2-5*01 ASSEAGTPLGETQY TRAV8-4*01 TRAJ31*01 AVNDRDNNARVI 
 
22. TRBV5-6*01 TRBD1*01 TRBJ1-5*01 ASSLAYRETYQPQY TRAV25*01 TRAJ20*01 AGEAYNNYKLS  3F1 
23. TRBV5-6*01 TRBD1*01 TRBJ1-5*01 ASSLAYRETYQPQY TRAV25*01 TRAJ20*01 AGEAYNNYKLS 
24. TRBV5-6*01 TRBD1*01 TRBJ1-5*01 ASSLAYRETYQPQY TRAV25*01 TRAJ20*01 AGEAYNNYKLS 
 
25. TRBV5-1*01 TRBD2*01 TRBJ2-1*01 ASSLGWGELNEQF TRAV8-6*02 TRAJ33*01 AVSGDSNYQLI 
26. TRBV5-1*01 TRBD2*01 TRBJ2-1*01 ASSLGWGELNEQF TRAV8-6*02 TRAJ33*01 AVSGDSNYQLI 
 
27. TRBV5-5*01 TRBD1*01 TRBJ1-1*01 ASSLGQLNTEAF  TRAV26-1*01 TRAJ43*01 IGRFGNDIR 
28. TRBV5-5*01 TRBD1*01 TRBJ1-1*01 ASSLGQLNTEAF  TRAV26-1*01 TRAJ43*01 IGRFGNDIR 
 
29.  TRBV10-1*01 –  TRBJ1-1*01 ASFSSLNTEAF  TRAV25*01 TRAJ22*01 SSIFCDSGWQLT 
30. TRBV10-1*01 –  TRBJ1-1*01 ASFSSLNTEAF  TRAV25*01 TRAJ22*01 SSIFCDSGWQLT 
 
31. TRBV10-1*01 TRBD2*01 TRBJ2-1*01 ASSEDWGGFYGEQF TRAV38-2 TRAJ53*01 AYRGSSNYKLT 
32. TRBV10-1*01 TRBD2*01 TRBJ2-1*01 ASSEDWGGFYGEQF TRAV38-2 TRAJ53*01 AYRGSSNYKLT 
 
33.  TRBV12-3*01 –  TRBJ2-7*01 ASKKSSYEQY  TRAV6*01 TRAJ34*01 ALHNANKLI 
34. TRBV12-3*01 –  TRBJ2-7*01 ASKKSSYEQY  TRAV6*01 TRAJ34*01 ALHNANKLI 
 
35. TRBV2*01 –  TRBJ2-7*01 ASRLYEQY  TRAV5*01 TRAJ30*01 AENREDKII 
36. TRBV2*01 TRBD2*01 TRBJ2-4*01 PAVMRRGEAKTLST TRAV19*01 TRAJ33*01 ALNEAEDSNYQLI 
37. TRBV2*01 TRBD1*01 TRBJ2-7*01 ATRTDLYEQY  TRAV20*01 TRAJ53*01 AVNSGSSNYKLT 
38. TRBV2*01 TRBD1*01 TRBJ2-3*01 ASSRTGGMNTDPQY TRAV22*01 TRAJ32*01 AVLYYGGSGNKLI 
39. TRBV2*01 –  TRBJ1-5*01 ASSDLSNQPQY  TRAV26-1*01 TRAJ5*01 IVRPPDTGRRALT 1D4 
40. TRBV2*01 –  TRBJ1-1*01 ASSELRNTEAF  TRAV36  TRAJ29*01 CAQFRNRAFV 
41. TRBV3-1*01 TRBD2*01 TRBJ2-1*01 ASSQDGGADNEQF TRAV9-1*01 TRAJ28*01 ALNLGYSGAGSYQLT 
42. TRBV3-1*01 TRBD2*02 TRBJ1-2*01 ASSQGRGNYDYT TRAV18*01 TRAJ10*01 VLKGASNKLT 
43. TRBV3-2*01 –  TRBJ2-5*01 ASTSFGDAVETQY TRAV6*01 TRAJ40*01 ALDASTTGNYKYI 
44. TRBV3-2*01 TRBD1*01 TRBJ1-4*01 ASSQQQATNEKLF TRAV9-2*01 TRAJ6*01 ALTHPSGGGYVLT 
45. TRBV5-1*01 –  TRBJ1-4*01 ASSVNEKLF  TRAV12-3*01 TRAJ2*01 AMTLGGTIDKLT   
46. TRBV5-1*01 TRBD1*01 TRBJ2-3*01 ASSIRDRGEDPQY TRAV23  TRAJ37*02 AASEASSNTGKLI  1B9 
47. TRBV5-5*01 TRBD1*01 TRBJ1-1*01 ASSLGQLNTEAF  TRAV26-1*01 TRAJ49*01 IVGFGNQL 
48. TRBV5-6*01 TRBD2*02 TRBJ2-1*01 ASSRLGGAHGEQF TRAV4*01 TRAJ36*01 LVGDGSWGKQPV 
49. TRBV5-6*01 TRBD1*01 TRBJ1-5*01 ASSLEQGRNQPQY TRAV12-3*01 TRAJ24*02 AMRADSWGKLQ 
50. TRBV5-6*01 TRBD1*01 TRBJ1-5*01 ASRQANREIYQPQY TRAV25*01 TRAJ20*01 AGEASNNYKLS 
51. TRBV5-6*01 TRBD1*01 TRBJ2-3*01 ASTLAGRGRSHPQY TRAV25*01 TRAJ20*01 AGEASNNYKLS 
52. TRBV5-6*01 TRBD1*01 TRBJ2-7*01 ASSRGRQTYEQY TRAV38-1*01 TRAJ43*01 AFMIYNNNDIR 
53. TRBV5-8*01 –  TRBJ2-3*01 ASSLGHPPPQS  TRAV26-1*01 TRAJ43*01 IGRFGNDIR 
54. TRBV6-1*01 TRBD1*01 TRBJ2-5*01 ASSETGDQETQ  TRAV12-2*02 TRAJ22*01 AVYPDSGWQLT  1G9 
55. TRBV6-1*01 TRBD1*01 TRBJ1-6*02 ASSEYRVSYNSPLH TRAV14  TRAJ30*01 AMMNRDDKII 
56. TRBV6-1*01 TRBD1*01 TRBJ2-4*01 ASTPGQTSQNTQY TRAV20*01 TRAJ9*01 AVQAWTGGFKTV 
57. TRBV6-1*01 TRBD2*01 TRBJ1-3*01 KWPEVGGFRKHHV TRAV21*01 TRAJ9*01 AVGYTGGFKTV 
58. TRBV6-1*01 TRBD1*01 TRBJ2-7*01 ASTKQGPQDEQY TRAV29  TRAJ52*01 ASCGAGYGKLT 
59. TRBV6-5*01 TRBD1*01 TRBJ1-1*01 GSSEGVKTEAF  TRAV3*01 TRAJ40*01 AVNEVSGNYKYI 
60. TRBV6-5*01 TRBD2*01 TRBJ2-5*01 LSPSVTKRPST  TRAV3*01 TRAJ40*01 AVNEVSGNYKYI 
61. TRBV6-5*01 –  TRBJ2-6*01 GSSVSSGASVLT  TRAV18*01 TRAJ8*01 VVHRLSETR 
62. TRBV7-2*01 –  TRBJ2-1*01 ASSLLALNEQF  TRAV17*01 TRAJ48*01 VTEGFGNEKLT 
63. TRBV7-2*01 TRBD2*01 TRBJ1-2*01 ASRPGGYDYT  TRAV19*01 TRAJ52*01 ALNEESWWCWLWKAD 
64. TRBV7-2*01 –  TRBJ2-1*01 ASSLLALNEQF  TRAV26-2*01 TRAJ48*01 LLGRGVEVRNP 
65. TRBV7-2*01 –  TRBJ1-2*01 ASRDSMSMDDYT TRAV29  TRAJ52*01 AARGSGYGKLT 
66. TRBV7-2*01 TRBD1*01 TRBJ2-5*01 ASSLVGSRVTETQY TRAV38-1*01 TRAJ42*01 AFMKHEVYGGSQGNLI 
67. TRBV7-4*01 TRBD1*01 TRBJ2-3*01 ASSGRDRDLADPQY TRAV18*01 TRAJ4*01 VLPAGGGYDKLI 
68. TRBV7-6*01 TRBD1*01 TRBJ2-7*01 ASSSLQTDWGDFYEQY TRAV12-3*01 TRAJ37*02 AMSVTSNTGKLI 
69. TRBV7-6*01 TRBD1*01 TRBJ2-1*01 ASSPDWGEGSPSEQF TRAV13-2*01 TRAJ47*02 AEMDYGNKLI 
70. TRBV7-6*01 TRBD2*01 TRBJ2-4*01 ASSPGPRRGAVNRLY TRAV16*01 TRAJ54*01 ALSGSLGAQKLV 
71. TRBV7-9*01 TRBD2*02 TRBJ2-7*01 ASSGSQPSYEQY TRAV13-1*01 TRAJ33*01 AATPGSNYQLI 
72. TRBV7-9*01 TRBD1*01 TRBJ2-4*01 ASSLGTPGNTQY  TRAV16*01 TRAJ16*01 ALKSSDGQKLL 
73. TRBV9*01 –  TRBJ2-2*01 PAANFMETPRSCS TRAV26-1*01 TRAJ22*01 IVRPPSDSGWQLT 
74. TRBV9*01 –  TRBJ2-1*01 ASSEVGYGEQF  TRAV35*01 TRAJ32*01 AGQKGGGGSGNKLI 
75. TRBV9*01 TRBD1*01 TRBJ2-1*01 ATGELGNGDQF  TRAV35*01 TRAJ32*01 AGQKGGGGSGNKLI 
76. TRBV10-1*01 –  TRBJ2-1*01 ASSEINALYGEQF TRAV8-6*02 TRAJ24*02 AVTTDSWGKLQ 
77. TRBV10-1*01 –  TRBJ1-1*01 ASFSSLNTEAF  TRAV25*01 TRAJ22*01 SSISSDSGWQLT 
78. TRBV10-1*01 –  TRBJ1-1*01 ASFSSLNTEAF  TRAV25*01 TRAJ22*01 STIYCGCGSQLT 
79. TRBV12-3*01 TRBD1*01 TRBJ2-7*01 ASTTPGQVSEQY  TRAV22*01 TRAJ40*01 AVTTGNYKYI 
80. TRBV12-3*01 TRBD1*01 TRBJ2-1*01 ASSLKWGSSYNEQF TRAV23  TRAJ27*01 AAGDNAGKLT 
81. TRBV13*01 –  TRBJ2-7*01 ASNFVSIYEQY  TRAV2*01 TRAJ27*01 AVLHTNADKLT 
82. TRBV13*01 TRBD1*01 TRBJ1-1*01 TSREGRGLGNEAF TRAV9-1*01 TRAJ27*01 ALEAGKLT 
83. TRBV14*01 TRBD2*02 TRBJ1-3*01 ASSQAEGTISGNTVY TRAV2*01 TRAJ11*01 AVEDSGYSTLT 
84. TRBV14*01 TRBD2*02 TRBJ2-3*01 ASSLWEGRDPQY TRAV2*01 TRAJ23*01 AVEDQDQAGKLI 
85. TRBV14*01 TRBD1*01 TRBJ1-5*01 ASSQGGGSQPQY TRAV3*01 TRAJ34*01 AVRDPNANKLI 
86. TRBV14*01 TRBD1*01 TRBJ1-2*01 ASTSRDIHDYT  TRAV17*01 TRAJ44*01 ATDSFTGIASKLT 
87. TRBV14*01 TRBD1*01 TRBJ1-5*01 PGGRVAISPS  TRAV19*01 TRAJ32*01 APAGGYGGRGNKLI 
88. TRBV15*01 TRBD1*01 TRBJ2-4*01 ASSKDMGTEGTKTFSS TRAV26-1*01 TRAJ48*01 IVRARQGGNENLT 
89. TRBV15*02 TRBD1*01 TRBJ1-2*01 ASSKKGQVSHST  TRAV16*01 TRAJ54*01 AQRVITQGAQKLV 
90. TRBV20-1*01 TRBD2*01 TRBJ2-7*01 SAPGLASSYEQY  TRAV9-1*01 TRAJ31*01 ALRQNNNARVI 
91. TRBV20-1*01 TRBD1*01 TRBJ1-2*01 SATLGTEFFRDYT TRAV12-1*01 TRAJ23*01 AVNMAYNQAGKLI 
92. TRBV20-1*01 TRBD1*01 TRBJ1-3*01 SARMQGTRITVY  TRAV38-2 TRAJ33*01 AYRGNMDSNYQLI 
93. TRBV23-1*01 TRBD1*01 TRBJ2-3*01 ASTGFGDPQY  TRAV9-2*01 TRAJ13*01 ALSSGSYQKVT 
94. TRBV23-1*01 TRBD1*01 TRBJ2-3*01 ASTGFGDPQY  TRAV9-2*01 TRAV9-2*01 ALSSGSTRESS 
95. TRBV23-1*01 TRBD1*01 TRBJ2-3*01 ASKQGWGHRSSV TRAV18*01 TRAJ33*01 VLRDPMDSNYQLI 
96. TRBV23-1*01 –  TRBJ2-3*01 ASSQGWGTDPQY TRAV18*01 TRAJ33*01 VLRDPMDSNYQLI 
97. TRBV24-1*01 TRBD1*01 TRBJ1-2*01 ATSDLSITGADYDYT TRAV12-3*01 TRAJ32*01 ARPGGSGNKLI 
98. TRBV27*01 TRBD2*01 TRBJ2-1*01 ASSGGPGQF  TRAV1-2*01 TRAJ34*01 AVRANKL 
99. TRBV27*01 TRBD1*01 TRBJ1-1*01 ASSKGGGNTEAF  TRAV6*01 TRAJ24*02 APGSDSWGKLQ 
100. TRBV27*01 TRBD1*01 TRBJ1-5*01 ASTPLGESNQPQY TRAV8-4*01 TRAJ11*01 AVILNSGYSTLT 
101. TRBV27*01 –  TRBJ2-1*01 ASSLRDFDGEQF  TRAV25*01 TRAJ21*01 AGMDNFNKFY 
102. TRBV27*01 –  TRBJ1-3*01 ASSSWQPSYSGNTVY TRAV29  TRAJ30*01 GGRDDKII 
103. TRBV28*01 TRBD1*01 TRBJ1-1*01 ASSFWRGVNTEAF TRAV8-3*02 TRAJ12*01 HNGATGDNKLI 
104. TRBV28*01 TRBD1*01 TRBJ1-1*01 ASSFWRGVNTEAF TRAV8-3*01 TRAJ50*01 GAGATSYNKLT 
105. TRBV28*01 –  TRBJ2-6*01 ASLDSGASVLT  TRAV12-3*01 TRAJ41*01 AMTHSNSGYALN 
106. TRBV29-1*01 TRBD1*01 TRBJ1-2*01 SVGTGYNYDYT  TRAV4*01 TRAJ30*01 LVGERDDKII 
107. TRBV29-1*01 –  TRBJ2-1*01 SVASLGFSYGEQF TRAV12-3*01 TRAJ43*01 AMKKDNNDIR 















Supplemental Table S2. Nucleotide sequence of PCR primers and PCR conditions. 
 
Primer name  TCRb primer sequence 
5A9_b_F  5’-TTCAGTCGACTGGATCCAGCCGCCATGGGCACCAGGCTCCT-3’ 
5A9_b_R  5’-GGTCACGTTCCTCAGGTCAACAGTTAACTTGGTCCCTG-3’ 
5B1_b_F  5’-TTCAGTCGACTGGATCCAGCCACCATGTGCCTCAGACTTCT-3’ 
5B1_b_R  5’-GGTCACGTTCCTCAGGTCCTCTACAACAGTTAACTTG-3’ 
4C2_b_F  5’-TTCAGTCGACTGGATCCAGCCGCCATGGATACCTGTCTCCT-3’ 
4C2_b_R  5’-GGTCACGTTCCTCAGGTCCTCTACAACTGTGAGTCTGG-3’ 
4D3_b_F  5’-TTCAGTCGACTGGATCCAGCCGCCATGGGCCCCGGGCTCCT-3’ 
4D3_b_R  5’-GGTCACGTTCCTCAGGTCCTCGAGCACTGTCAGCCGGG-3’ 
3E5_b_F  5’-TTCAGTCGACTGGATCCAGCCGCCATGGATACCTGGCTCCT-3’ 
3E5_b_R  5’-GGTCACGTTCCTCAGGTCCTCGAGCACCAGGAGCCGCG-3’ 
3F1_b_F  5’-TTCAGTCGACTGGATCCAGCCGCCATGGGCCCCGGGCTCCT-3’ 
3F1_b_R  5’-GGTCACGTTCCTCAGGTCCTCTAGGACGGAGAGTCGAG-3’ 
1B9_b_F  5’-TTCAGTCGACTGGATCCAGCCGCCATGCTGTTTTGCTGGGCA-3’ 
1B9_b_R  5’-GGTCACGTTCCTCAGGTCCTCGAGCACTGTCAGCCGGG-3’ 
1D4_b_F  5’-TTCAGTCGACTGGATCCAGCCACCATGGATACCTGGCTCCT-3’ 
1D4_b_R  5’-GGTCACGTTCCTCAGGTCCTCTAGGACGGAGAGTCGAG-3’ 
1G9_b_F  5’-TTCAGTCGACTGGATCCAGTTCCCCTTTCATCAATGC-3’ 
1G9_b_R  5’-GGTCACGTTCCTCAGGTCCTCTAGCACCAGGAGCCGCG-3’ 
1385_b_F  5’-TTCAGTCGACTGGATCCAGCCGCCATGGGCACCAGGCTCCTCTG-3’ 




   TCRa primer sequence 
5A9_a_F  5’-GAGGAGAATCCTGGCCCAATGGACAAGATCTTAGGAGC-3’ 
5A9_a_R  5’-CGGGCTCTGGGTTCTGGATATTCAGGTTGATGCTCAGCC-3’ 
5B1_a_F  5’-GAGGAGAATCCTGGCCCAATGACATCCATTCGAGCTGT-3’ 
5B1_a_R  5’-CGGGCTCTGGGTTCTGGATATTCAGTTCCACTTTTAGCT-3’ 
4C2_a_F  5’-GAGGAGAATCCTGGCCCAATGATGAAGTGTTCACAGGC-3’ 
4C2_a_R  5’-CGGGCTCTGGGTTCTGGATATTTGGAATCACAGAAAGTC-3’ 
4D3_a_F  5’-GAGGAGAATCCTGGCCCAATGGTCCTGAAATTCTCCGT-3’ 
4D3_a_R  5’-CGGGCTCTGGGTTCTGGATATTTGGATAGACAGTTAAGA-3’ 
3E5_a_F  5’-GAGGAGAATCCTGGCCCAATGCTCCTGCTGCTCGTCCT-3’ 
3E5_a_R  5’-CGGGCTCTGGGTTCTGGATATTGGGCTTCACCACCAGCT-3’ 
3F1_a_F  5’-GAGGAGAATCCTGGCCCAATGCACACATCTGCTTTCCA-3’ 
3F1_a_R  5’-CGGGCTCTGGGTTCTGGATATTTGCTCTTACAGTTACTG-3’ 
1B9_a_F  5’-GAGGAGAATCCTGGCCCAATGGACAAGATCTTAGGAGC-3’ 
1B9_a_R  5’-CGGGCTCTGGGTTCTGGATATCTGGTTGTACTTGTAAAG-3’ 
1D4_a_F  5’-GAGGAGAATCCTGGCCCAATGAGGCTGGTGGCAAGAGT-3’ 
1D4_a_R  5’-CGGGCTCTGGGTTCTGGATATTTGGTTGCACTTGGAGTC-3’ 
1G9_a_F  5’-GAGGAGAATCCTGGCCCAATGATGAAATCCTTGAGAGT-3’ 
1G9_a_R  5’-CGGGCTCTGGGTTCTGGATATCAGGTACAACGGTCAATT-3’ 
1385_a_F  5’-GAGGAGAATCCTGGCCCAATGAAGACACTTACTGGATC-3’ 




RT primer sequence 
RTa   5’-CAGCGGTGTTTGGCAGCTCTTC-3’ 
RTb1   5’-CTGGCAAAAGAAGAATGTAT-3’ 
RTb2   5’-ACACAGATTGGGAGCAGGTA-3’ 
 
First PCR primer sequence 
F1st   5’-TCAAGCAGTAGCAGCAGTTCGATAAGGATCCCCCCCCCCCCCDN-3’ 
R1sta   5’-GAGAGGGAGAGGAGGGGCGAT-3’ 
R1stb1   5’-TCACAACGGGTTAGAAGCTC-3’ 
R1stb2   5’-GGATGAAGAATGACCCGGGAT-3’ 
 
Second PCR primer sequence 
F2nd   5’-AGCAGTAGCAGCAGTTCGATA-3’ 
R2nda   5’-AGTAAATAGGCAGACAGAGGT-3’ 
R2ndb1   5’-GTGGTCGGGGTAGAAGCCTGT-3’ 
R2ndb2   5’-GTGGTCGGGGTAGAAGCCTGT-3’ 
First PCR condition 
1) 94˚C, 2 min 
2) 98˚C, 10 sec 
3) 68˚C, 30 sec (-2˚C / cycle) 
4) 68˚C, 1 min 30 sec 
5) Go to 2), Repeat 4 times 
6) 98˚C, 10 sec 
7) 60˚C, 30 sec 
8) 68˚C, 1 min 30 sec 
9) Go to 6), Repeat 24 times 
10) 68˚C 10 min 
11) 12˚C 
 
Second PCR condition 
1) 94˚C, 2 min 
2) 98˚C, 10 sec 
3) 68˚C, 30 sec (-2˚C / cycle) 
4) 68˚C, 1 min 30 sec 
5) Go to 2), Repeat 4 times 
6) 98˚C, 10 sec 
7) 60˚C, 30 sec 
8) 68˚C, 1 min 30 sec 
9) Go to 6), Repeat 29 times 
10) 68˚C 10 min 
11) 12˚C 
 
 
 
 
